Brominated Vegetable Oil vs Butylated Hydroxyanisole: which is worse?

What is Brominated Vegetable Oil?

Brominated vegetable oil (BVO) is a food additive created by bonding bromine atoms to vegetable oil (typically soybean oil), creating a denser-than-water compound. When added to citrus-flavored beverages, BVO acts as an emulsifier and weighting agent, keeping citrus flavor oils evenly distributed throughout the drink rather than floating to the surface.

What is Butylated Hydroxyanisole?

Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum. It is a mixture of two isomeric compounds (2-BHA and 3-BHA). BHA prevents fats and oils from oxidizing (going rancid), extending shelf life. Its chemical formula is C11H16O2.

Documented risks

Brominated Vegetable Oil: BVO's health concerns center on bromine accumulation in body fat and tissues. Bromine is a halogen related to iodine, and it competes with iodine in the body, potentially disrupting thyroid function—a critical concern since iodine is essential for thyroid hormone synthesis. The FDA-NIH collaborative research directly triggering the 2024 ban found adverse cardiac and thyroid effects in animal studies. This FDA-NIH work, published around 2022–2023, showed effects at dose levels closer to realistic human exposure than previous studies, removing the basis for BVO's safety determination under the Federal Food, Drug, and Cosmetic Act's 'reasonable certainty of no harm' standard. Historical case reports of human toxicity from excessive BVO consumption document bromoderma (skin lesions), memory loss, nerve damage, tremors, and fatigue in individuals consuming large volumes of BVO-containing beverages daily. Two well-documented US cases from the 1970s and 1980s involved bromism (bromine toxicity) from chronic overconsumption. Bromine bioaccumulates in fatty tissues. Long-term sub-clinical accumulation was a concern even before the FDA ban, particularly for heavy consumers of citrus sodas. The EU, Japan, and other countries banned BVO decades ago, making the US one of the last major markets to revoke approval. The FDA issued a proposed rule in November 2023 and a final rule on July 3, 2024, effective August 2, 2024, with compliance deadline August 2, 2025, after which BVO-containing products may not be manufactured for US sale.

Butylated Hydroxyanisole: BHA is classified by the International Agency for Research on Cancer (IARC) as Group 2B (possible human carcinogen) based on studies showing it causes papillomas and squamous cell carcinomas of the forestomach in rats, hamsters, and mice at high doses. A 1983 NTP bioassay confirmed these findings. The National Toxicology Program lists BHA as 'reasonably anticipated to be a human carcinogen' in its Report on Carcinogens. The forestomach is an anatomical structure found in rodents but not humans, creating some uncertainty about direct extrapolation. EFSA's 2012 re-evaluation (EFSA Journal 2012;10(10):2588) concluded that BHA may have endocrine-disrupting potential based on animal data showing interactions with estrogen receptors and androgenic hormone pathways. EFSA found the ADI of 1 mg/kg body weight but noted concerns about endocrine effects. Japan banned BHA for use in foods containing fats and oils, consistent with its generally precautionary approach to synthetic food preservatives. In cosmetics, the EU Scientific Committee on Consumer Safety (SCCS) has assessed BHA and found potential endocrine-disrupting effects at dermal exposure levels. EWG rates BHA as high-concern in Skin Deep cosmetics database. The antioxidant paradox applies: while BHA prevents lipid oxidation in foods, it may paradoxically act as a pro-oxidant in certain biological contexts at certain doses.